Spotlight On... Spark buys out a gene therapy partner; KaloBios names new CEO in Shkreli's shadow; and more...

Spark Therapeutics ($ONCE) is trading roughly $15 million in cash and stock to buy out one of its partners, picking up Genable Technologies and its candidate for a rare vision disorder. Under the agreement, Spark paid $6 million in cash and 265,000 of its own shares to absorb the Irish biotech, following a collaboration agreement signed in 2014. Genable has been using Spark's in-house gene therapy technology to develop a candidate called RhoNova, designed to treat the genetic defect behind rhodopsin-linked autosomal dominant retinitis pigmentosa, an orphan disease that can result in blindness. Genable's treatment has demonstrated promising results in preclinical studies, Spark said, and the company plans to push it into clinical trials. More

@FierceBiotech: Celldex's cancer vaccine Rintega implodes in glioblastoma PhIII. News | Follow @FierceBiotech

@JohnCFierce: AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug. Report | Follow @JohnCFierce

> KaloBios, delisted from Nasdaq after the arrest of former CEO Martin Shkreli, has appointed a new chief to help it stay afloat, recruiting board member Cameron Durrant. Item

> BioCryst ($BCRX) said its in-development antiviral therapy demonstrated promise in a preclinical study on mice with Zika virus. Story

Medical Device News

@FierceMedDev: ICYMI: Siemens Healthcare CEO: restructured unit 'hungry' for M&A deals. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: AZ stokes $45B sales hopes with expanded approval for breast cancer drug Faslodex. More | Follow @EmilyWFierce

> FDA nod for smart contact lens that continuously monitors eye pressure changes in glaucoma. More

> Next up on Thermo Fisher's to-do list? Some serious M&A: Analyst. Report

> Senators butt heads over proposed device (and drug) industry regulatory overhaul. Article

Pharma News

@FiercePharma: Heska's topsy-turvy year ends on a high note as earnings beat estimates. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Victoza comes up big for Novo with key heart-risk lowering data. More | Follow @CarlyHFierce

> How Venezuela's meltdown delivered a mega-hit to Big Pharma: Reuters. Story

> The potential to restrict generics with REMS is growing and it doesn't bode well for biosimilars. More

> Big Pharma wields big influence in Kentucky for restrictive biosimilars law. Article

Pharma Marketing News

> With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land. Report

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Item

> J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL. More

> DTC challenges mount as senators roll out bill to yank tax deduction. Story

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Article

Animal Health News

> Kindred projects increased spending as it preps for first commercial product. Item

> VCA adds 56 veterinary clinics by snapping up $344M stake in Las Vegas chain. Report

> Heska's topsy-turvy year ends on a high note as record earnings beat estimates. More

> Under pressure from activists, In-N-Out Burger jumps on antibiotic-free bandwagon. Story

> Zoetis launches first genomic test for predicting common diseases in Holsteins. Article

Biotech IT News

> Bristol-Myers signs deal to use Veeva tools for regulatory information. News

> U.K. firms team up to develop mental health-tracking wearable devices. Report

> GSK extends business process analytics contract to 2020. Story

> George Church's Veritas starts $999 whole-genome sequencing service. Item

> IPhone-based Parkinson's study shares 6 months of data on 9,500 participants. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.